Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused…
0,906$
-73,74%
Echtzeit-Aktienkurs Minerva Neurosciences
Bid:
Ask:
Nachrichten zur Minerva Neurosciences Aktie
Form 8-K Minerva Neurosciences, For: Dec 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET...…
Minerva Neurosciences GAAP EPS of -$1.29 beats by $0.03
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Minerva Neurosciences, For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Minerva Neurosciences Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on…
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers
Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million…
Minerva Neurosciences Shares Drop 58% After FDA Refusal to File Letter
Minerva Neurosciences Shares Drop 58% After FDA Refusal to File Letter...…
Minerva Neurosciencs to request meeting with FDA about schizophrenia drug
Minerva Neurosciences Inc. said Monday that it received a refusal to file letter from the Food and Drug Administration…
Minerva Neurosciences Gets Refusal to File Letter From FDA for Roluperidone
Minerva Neurosciences Gets Refusal to File Letter From FDA for Roluperidone...…
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused…